SBI² Conference Scientific Program

8:00am - 5:00pm Registration Open
8:00am - 6:30pm Poster Viewing

8:50 - 9:00	Introduction & Welcome to the 6th Annual SBI2 Conference. Myles Fennell, President SBI2
9:10 - 10:00	Opening Keynote Presentation.
	Integrating Cellular and Spatial Maps for a Human Cell Atlas Aviv Regev
	Institute Member, Chair of the Faculty, Co-director of the Cell Circuits Program, Broad Institute

Session I:         HCS-HTS successes and learnings (10:10am - 12:30pm)

Session Chairs & Scientific Program Committee:

High content screening allows us to interrogate simultaneously many cellular parameters representative of the biological activity present in physiologically and disease relevant cell-based assays.   By exploring high dimensional phenotypic signatures, complex biological pathways can be mapped so that novel drugs with subtle effects or complex mechanism of actions may finally be identified. The HCS-HTS success and learning session at the 6^th Annual SBI2 conference will cover success stories and lessons learned when applying these complex assays to drug discovery in industry and academia.

Session II: Focus on Imaging in Neurological Disease and Oncology (1:50pm - 5:00pm)

Session Chairs & Scientific Program Committee:

Phenotypic screening is increasingly dependent on modeling, computational approaches and 3D imaging to attack complex biological problems at both high-content and high-throughput. This has been especially empowering in oncology and neuroscience where the use of pluripotent stem cells, self-organized organoids and whole animal models are enabling screens for a range of cellular phenotypes from the electrophysiological profile of individual neurons to their degeneration. This session will highlight recent developments that expand our ability to understand the local environment in tumor progression and degeneration and regeneration of the nervous system.

SBI² Conference Scientific Program

8:00am - 3:00pm Exhibit & Poster viewing

8:50 - 9:00  Day 2 Opening Remarks. Myles Fennell, President SBI2

Session III:            Therapeutic Drug Discovery for Complex Disease. (9:00am - 2:20pm)

Session Chairs & Scientific Program Committee:

How HCS technologies and other imaging modalities support the understanding of complex diseases
Novel technologies such as 3D models and digital pathology are transforming drug development through the quality, complexity and human-relevance of the data they produce. In particular, recent advances in Organ-Chip and organoid technologies have provided new disease models that more closely recapitulate human disease, while advances in digital pathology and image analysis allow for the appreciation of spatial relationships within the tissue microenvironment. In this session we explore these technologies and address their potential to reveal mechanisms for therapeutic response.

9:00 - 9:30	Structure-function relationships in human organ models Invited Speaker, Janna Nawroth, (Emulate Inc)
9:30 - 10:00	Phenotyping the tumor micro-environment with advanced tissue- based multiplexing assays. Invited Speaker, Bonnie Philipps, (Ultivue Inc)
10:00 - 10:20	Maximizing the Value of Cancer Drug Screening in Multicellular Tumor Spheroid Cultures: Are you Analyzing your 3D Tumor Models Appropriately? Selected Abstract, Paul Johnston, (U of Pittsburg)
10:20 - 10:30	Introducing two software modules that bring new functionality in image acquisition and analysis software from Amnis, now a part of Luminex Corporation 10 Minute Spotlight, Darin Fogg, (Lunimex)
10:30 - 11:00	Break for coffee & exhibit viewing
10:30 - 12:00	Poster Presentations (authors at posters)
	SBI2 High Content 2019 Poster Competition Sponsored by ChemBridge: 1st, 2nd, & 3rd place awards
12:15 - 1:00	GE Healthcare Technology Spotlight Lunch (Pechet Room, overflow rooms 214, 216, 217) Diving Deeper: Advances in 3D High Content Screening Solutions and Quantitative Image Analysis Speaker, Will Marshall, (GE)
1:15 - 2:15	Closing Keynote Presentation.
	From Yeast to Neurons to Patients: A Novel Drug Discovery Platform for Neurodegenerative diseases. Chee-Yeun Chung
	Scientific Co-Founder, Director, Discovery Biology Yumanity Therapeutics

Session IV:           Machine Learning/Artificial Intelligence and/or Conventional outputs?
(2:00pm - 4:30pm)

Session Chairs & Scientific Program Committee:

Machine learning has been a feature of drug discovery for almost four decades and delivered multiple successes, with early algorithms focused around in silico optimization of compounds. So what’s all the fuss about now? In contrast to the rules and simulation based approaches of past decades, new machine learning approaches such as deep-learning allow us to extract valuable insights from a wide variety of data types, including imaging, sequencing, and compound data, without having to explicitly engineer new features for each data type. In this session we will bring together a group of researchers working on state-of-the art techniques for microscopy image analysis, and explore how imaging data can be integrated with other data modalities to answer key questions in biological and pharmaceutical research.